FI861966A - Renad och tre gaonger klonad hepatit-a-virus. - Google Patents

Renad och tre gaonger klonad hepatit-a-virus. Download PDF

Info

Publication number
FI861966A
FI861966A FI861966A FI861966A FI861966A FI 861966 A FI861966 A FI 861966A FI 861966 A FI861966 A FI 861966A FI 861966 A FI861966 A FI 861966A FI 861966 A FI861966 A FI 861966A
Authority
FI
Finland
Prior art keywords
virus
renad
gaonger
clonad
hepatit
Prior art date
Application number
FI861966A
Other languages
English (en)
Other versions
FI86376C (fi
FI861966A0 (fi
FI86376B (fi
Inventor
Richard J Daemer
Stephen M Feinstone
Robert H Purcell
Ian D Gust
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24615385&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI861966(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health filed Critical Us Health
Publication of FI861966A publication Critical patent/FI861966A/fi
Publication of FI861966A0 publication Critical patent/FI861966A0/fi
Application granted granted Critical
Publication of FI86376B publication Critical patent/FI86376B/fi
Publication of FI86376C publication Critical patent/FI86376C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/08—Inactivation or attenuation by serial passage of virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32461—Methods of inactivation or attenuation
    • C12N2770/32464—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
FI861966A 1984-09-19 1986-05-12 Foerfarande foer framstaellning av renad och tre gaonger klonad hepatitis-a-virus. FI86376C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65206784 1984-09-19
US06/652,067 US4620978A (en) 1982-04-07 1984-09-19 Hepatitis A virus purified and triply cloned
US8501769 1985-09-18
PCT/US1985/001769 WO1986001826A1 (en) 1984-09-19 1985-09-18 Hepatitis a virus purified and triply cloned

Publications (4)

Publication Number Publication Date
FI861966A true FI861966A (fi) 1986-05-12
FI861966A0 FI861966A0 (fi) 1986-05-12
FI86376B FI86376B (fi) 1992-05-15
FI86376C FI86376C (fi) 1992-08-25

Family

ID=24615385

Family Applications (1)

Application Number Title Priority Date Filing Date
FI861966A FI86376C (fi) 1984-09-19 1986-05-12 Foerfarande foer framstaellning av renad och tre gaonger klonad hepatitis-a-virus.

Country Status (16)

Country Link
US (1) US4620978A (fi)
EP (1) EP0196316A4 (fi)
JP (1) JPS62500659A (fi)
KR (1) KR860700263A (fi)
AU (1) AU583306B2 (fi)
CA (1) CA1260392A (fi)
DK (1) DK227786A (fi)
ES (1) ES8701837A1 (fi)
FI (1) FI86376C (fi)
GR (1) GR852293B (fi)
IL (1) IL76417A (fi)
NO (1) NO169601C (fi)
NZ (1) NZ213513A (fi)
PT (1) PT81150B (fi)
WO (1) WO1986001826A1 (fi)
ZA (1) ZA857134B (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894228A (en) * 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
USRE37381E1 (en) * 1982-04-07 2001-09-18 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US5268292A (en) * 1988-06-27 1993-12-07 Robertson Betty H Reproducible generation of high yields of hepatitis A virus by cell culture
ATE205536T1 (de) 1992-09-18 2001-09-15 Smithkline Beecham Biolog Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe
ES2162139T5 (es) * 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US4532215A (en) * 1982-04-07 1985-07-30 The United States Of America As Represented By The Department Of Health And Human Services Isolation of hepatitis A virus strain HM-175

Also Published As

Publication number Publication date
ZA857134B (en) 1987-05-27
EP0196316A4 (en) 1987-01-28
ES8701837A1 (es) 1986-12-01
AU4862085A (en) 1986-04-08
PT81150B (pt) 1987-10-20
KR860700263A (ko) 1986-08-01
DK227786D0 (da) 1986-05-16
IL76417A0 (en) 1986-01-31
NZ213513A (en) 1989-03-29
FI86376C (fi) 1992-08-25
US4620978A (en) 1986-11-04
NO169601B1 (no) 1992-04-06
AU583306B2 (en) 1989-04-27
CA1260392A (en) 1989-09-26
FI861966A0 (fi) 1986-05-12
FI86376B (fi) 1992-05-15
ES547115A0 (es) 1986-12-01
IL76417A (en) 1990-12-23
DK227786A (da) 1986-05-16
NO169601C (no) 1992-07-15
JPS62500659A (ja) 1987-03-19
NO861619A (no) 1986-04-24
PT81150A (en) 1985-10-01
GR852293B (fi) 1986-01-21
EP0196316A1 (en) 1986-10-08
WO1986001826A1 (en) 1986-03-27

Similar Documents

Publication Publication Date Title
ES2188583T3 (es) Polipeptidos para el virus de la hepatitis c (hcv).
DE69232906D1 (de) Detektion des Hepatis-C Virus.
FI861966A (fi) Renad och tre gaonger klonad hepatit-a-virus.
NO165478C (no) Fremgangsmaate for fremstilling av antigeniske preparater.
DE3788229T2 (de) Verfahren zur isolierung von ca 125-antigen.
FI923347A0 (fi) Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
FI882919A (fi) Foerfarande.
ATE6402T1 (de) Verfahren zur herstellung von hepatitis b oberflaechenantigen.
HK15184A (en) Fluor-containing 1,4-dihydrophyridines,pharmaceuticals containing them and process for their preparation
DK330086A (da) Addukt af cis-diklor-trans-dihydroxy-bis-(isopropylamin)-platin(iv) og fremgangsmaade til fremstilling deraf
PT625204E (pt) Terapeutica da hepatite
ATE1241T1 (de) Verfahren zur herstellung von 4,5-perfluor-1,3-dioxolanen.
DK0515415T3 (da) Hidtil ukendt vaccine og fremgangsmåde til fremstilling deraf
FR2681069B1 (fr) Nouveau procede de preparation de l'hydrocortisone et nouveaux intermediaires.
GR3023251T3 (en) cDNA sequence and detection of hepatits C virus
DE3787121D1 (de) Verfahren zur Herstellung und Verwendung von Katzenleukämievirus-Antigenen.
ATE39055T1 (de) Verfahren zur immunisierung von schweinen gegen die aujeszky-krankheit.
DK632187A (da) Ny forbedret fremgangsmaade til fremstilling af penicillansyrederivater
DK126288D0 (da) Fremgangsmaade til fremstilling af polychlorphosphazen
DE69113520T2 (de) Monoklonale Antikörper gegen HIV GP120.
DK0841954T3 (da) Fremgangsmåde til fremstilling af et virussikkert, terapeutisk, biologisk apparat
DE3880903D1 (de) Herstellungsverfahren eines cycloalkanols.
DE3775497D1 (de) Herstellungsverfahren von tribromotetramethylbiphenol und verwandten verbindungen.
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
TH3211EX (th) เฮพาไททิสเอไวรัสที่บริสุทธิ์และมีการโคลนสามครั้ง

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: THE UNITED STATES OF AMERICA

MA Patent expired